Opin vísindi

Fletta eftir höfundi "Bateman, Brian T."

Fletta eftir höfundi "Bateman, Brian T."

Röðun: Raða: Niðurstöður:

  • Icon
    Antipsychotic drug use in pregnancy: A multinational study from ten countries 
    Reutfors, Johan; Cesta, Carolyn E.; Cohen, Jacqueline M.; Bateman, Brian T.; Brauer, Ruth; Einarsdóttir, Kristjana; Engeland, Anders; Furu, Kari; Gissler, Mika; Havard, Alys; Hernandez-Diaz, Sonia; Huybrechts, Krista F.; Karlstad, Øystein; Leinonen, Maarit K.; Li, Jiong; Man, Kenneth K.C.; Pazzagli, Laura; Schaffer, Andrea; Schink, Tania; Wang, Zixuan; Yu, Yongfu; Zoega, Helga; Bröms, Gabriella (Elsevier BV, 2020-06)
    Aim: To compare the prevalence and trends of antipsychotic drug use during pregnancy between countries across four continents. Methods: Individually linked health data in Denmark (2000−2012), Finland (2005–2014), Iceland (2004–2017), Norway (2005–2015), ...
  • Icon
    Atomoxetine in Early Pregnancy and the Prevalence of Major Congenital Malformations : A Multinational Study 
    Bröms, Gabriella; Hernandez-Diaz, Sonia; Huybrechts, Krista F.; Bateman, Brian T.; Kristiansen, Eskild Bendix; Einarsdóttir, Kristjana; Engeland, Anders; Furu, Kari; Gissler, Mika; Karlsson, Pär; Klungsøyr, Kari; Lahesmaa-Korpinen, Anna Maria; Mogun, Helen; Nørgaard, Mette; Reutfors, Johan; Sørensen, Henrik Toft; Zoega, Helga; Kieler, Helle (2023-01-16)
    Objective: Most research on safety of attention-deficit/hyperactivity disorder (ADHD) medications during pregnancy concerns central nervous system stimulants, while little is known about the safety of atomoxetine, a primary treatment alternative. We ...
  • Icon
    Safety of GLP-1 Receptor Agonists and Other Second-Line Antidiabetics in Early Pregnancy 
    Cesta, Carolyn E.; Rotem, Ran; Bateman, Brian T.; Chodick, Gabriel; Cohen, Jacqueline M.; Furu, Kari; Gissler, Mika; Huybrechts, Krista F.; Kjerpeseth, Lars J.; Leinonen, Maarit K.; Pazzagli, Laura; Zoega, Helga; Seely, Ellen W.; Patorno, Elisabetta; Hernández-Díaz, Sonia (2024-02-05)
    Importance: Increasing use of second-line noninsulin antidiabetic medication (ADM) in pregnant individuals with type 2 diabetes (T2D) may result in fetal exposure, but their teratogenic risk is unknown. Objective: To evaluate periconceptional use of ...